scholarly journals Ocrelizumab for multiple sclerosis

2018 ◽  
Vol 56 (7) ◽  
pp. 80-84
Keyword(s):  
Multiple Sclerosis ◽  
Marketing Authorisation ◽  
Progressive Multiple Sclerosis ◽  
European Medicines Agency ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Early Primary

▼Ocrelizumab (Ocrevus - Roche Registration GmbH) has received marketing authorisation approval from the European Medicines Agency (EMA) for the treatment of adults with multiple sclerosis.1,2 It is the first drug to be licensed for use in early primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. Here, we review the evidence for the safety and effectiveness of ocrelizumab.

scholarly journals Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis

2007 ◽  
Vol 64 (3) ◽  
pp. 411 ◽  
Author(s):  
Francesco Manfredonia ◽  
Olga Ciccarelli ◽  
Zhaleh Khaleeli ◽  
Daniel J. Tozer ◽  
Jaume Sastre-Garriga ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Relaxation Time ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
T1 Relaxation Time ◽  
Primary Progressive ◽  
T1 Relaxation ◽  
Early Primary

scholarly journals Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study

Brain ◽  
2005 ◽  
Vol 128 (6) ◽  
pp. 1454-1460 ◽  
Author(s):  
Jaume Sastre-Garriga ◽  
Gordon T. Ingle ◽  
Declan T. Chard ◽  
Mara Cercignani ◽  
Lluís Ramió-Torrentà ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Longitudinal Study ◽  
White Matter ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
White Matter Volume ◽  
Volume Changes ◽  
Primary Progressive ◽  
Matter Volume ◽  
Early Primary

Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis

2006 ◽  
Vol 63 (8) ◽  
pp. 1175 ◽  
Author(s):  
Jorge Sepulcre ◽  
Jaume Sastre-Garriga ◽  
Mara Cercignani ◽  
Gordon T. Ingle ◽  
David H. Miller ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Gray Matter ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Gray Matter Atrophy ◽  
Early Primary

Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability

NeuroImage ◽  
2007 ◽  
Vol 37 (1) ◽  
pp. 253-261 ◽  
Author(s):  
Z. Khaleeli ◽  
M. Cercignani ◽  
B. Audoin ◽  
O. Ciccarelli ◽  
D.H. Miller ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Grey Matter ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Early Primary
Sign in / Sign up

Export Citation Format

Share Document